AI Maverick Intel Announces LOI to Acquire HEAL Access Canada

AI Maverick Intel Inc. (OTC: AIMV) has announced a non-binding letter of intent to acquire 100% of HEAL Access Canada Inc., a subsidiary of HEAL Group Holdings Inc. This transaction represents the first under the company's right of first refusal agreement with HEAL. The proposed acquisition includes 20 million exchangeable shares and a secured vendor take-back note valued at approximately $5 million. The parties are working toward executing a definitive agreement by May 29, 2026, subject to customary closing conditions and approvals.

The acquisition is expected to provide AI Maverick Intel with an initial operating platform within HEAL's AI-enabled healthcare ecosystem. AI Maverick Intel focuses on identifying and developing opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries. The company evaluates strategic acquisitions, partnerships, and technology platforms designed to create scalable growth opportunities. For the latest news and updates relating to AIMV, information is available in the company's newsroom at http://ibn.fm/AIMV.

This press release was distributed by InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio. InvestorWire provides advanced wire-grade press release syndication for private and public companies and the investment community. The platform offers access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution, and tailored corporate communications solutions. For more information about InvestorWire, please visit https://www.InvestorWire.com. Full terms of use and disclaimers applicable to all content provided by InvestorWire are available on its website at https://www.InvestorWire.com/Disclaimer.

The announcement is significant as it marks AI Maverick Intel's strategic move into the healthcare technology sector through acquisition. By gaining an operating platform within an established AI-enabled healthcare ecosystem, the company positions itself to leverage artificial intelligence and data platforms in a high-growth industry. The transaction structure, involving exchangeable shares and a vendor take-back note, indicates a negotiated arrangement that aligns the interests of both parties. The extended timeline for a definitive agreement allows for due diligence and regulatory processes, which are common in such transactions. For investors, this development represents a concrete step in AI Maverick Intel's stated strategy of pursuing strategic acquisitions to build shareholder value. The focus on healthcare aligns with broader market trends where AI applications in medicine, diagnostics, and healthcare management are attracting significant investment and innovation. The success of this proposed acquisition could influence the company's future direction and its ability to compete in the technology-enabled healthcare space.